Key messages
-
People with solid tumors who received primary preventative (prevention of a disorder before it ever occurs) use of medicines that increase the body's production of white blood cells (granulopoiesis-stimulating factors [GSFs]) after chemotherapy probably had fewer infections, but there may be little to no difference in the length of time from either the date of diagnosis or the start of treatment that they were still alive (overall survival).
-
Primary preventative use of GSFs probably increases the risk of bone pain in people receiving chemotherapy for solid tumors.
-
More high-quality studies are needed to improve our understanding of the effects of GSFs.
What is the relationship between granulopoiesis-stimulating factors and solid tumors?
Solid tumors are a type of cancer where the tumor is a solid mass of tissue. They can develop in many parts of the body, including the breasts, lungs, bones, and liver, and represent approximately 90% of adult cancers. Treatment of solid tumors often involves chemotherapy. One unwanted effect of chemotherapy is bone marrow suppression, where the bone marrow slows or reduces the production of new blood cells. This can lead to neutropenia (low levels of neutrophils, a type of white blood cell that helps fight infection), infection risks, and even reduced survival in people with solid tumors.
Granulopoiesis-stimulating factors (GSFs) can be used as a supportive treatment to chemotherapy to increase the body's production of white cells, and possibly improve disease control and reduce the death rate. The two main types of GSFs are granulocyte colony-stimulating factor (G-CSF), which mainly increases neutrophils, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates several types of infection-fighting blood cells. Several studies have found that using G-CSF before low white blood cell counts occur can reduce the risk of neutropenia and other complications of bone marrow suppression. However, it is still unclear whether GM-CSF has similar benefits. It is also unclear whether using G-CSF or GM-CSF to prevent low white blood cell counts can help people live longer when both study groups receive the same chemotherapy regimen.
What did we want to find out?
We wanted to find out the effects of giving G-CSF or GM-CSF to prevent low white blood cell counts compared with dummy treatment (placebo) or no preventative use on survival and preventing unwanted effects of cancer treatment in people with solid tumors.
What did we do?
We searched for studies that compared giving G-CSF or GM-CSF to prevent low white blood cell counts versus placebo or no preventative use in the treatment of solid tumors. We focused on people with solid tumors (for example, breast, lung, colorectal, and prostate cancers) and did not include people with blood cancers.
We compared and summarized the results of the studies and rated our confidence in the evidence based on factors such as study methods and sizes.
What did we find?
We found 26 studies that involved a total of 5320 participants with solid tumors. The studies compared the effectiveness and safety of various types of G-CSF or GM-CSF to placebo or no preventative use in high-and middle-income countries.
Main results
-
Compared with no preventative use, primary preventative (prevention of a disorder before it ever occurs) use of G-CSF or GM-CSF after chemotherapy:
-
likely reduces the risk of infection (7 studies, 915 people);
-
may result in little to no difference in overall survival (the length of time from either the date of diagnosis or the start of treatment that patients are still alive) (3 studies, 537 people) and freedom from treatment failure (1 study, 259 people); and
-
probably results in a large increase in risk of bone pain (10 studies, 3152 people).
-
-
There is likely little to no difference between study groups in death from any cause during chemotherapy (11 studies, 3001 people).
-
One study reported that people in the G-CSF group had a longer average hospitalization duration (9.7 days versus 5.2 days).
-
Quality of life was not reported in any of the included studies.
What are the limitations of the evidence?
Our confidence in the evidence ranged from moderate to low, and was reduced due to the following factors:
-
in some studies, people taking part in the study, as well as study personnel and those measuring the results, were aware of the treatment received;
-
results varied widely across studies, and the included studies involved small numbers of people;
-
the studies were done in different types of solid tumors or used different doses of GSFs.
How up to date is this evidence?
The evidence is current to June 2025.
阅读完整摘要
研究目的
To assess the efficacy of prophylactic granulopoiesis-stimulating factors compared with placebo or no prophylaxis on survival outcomes and preventing adverse effects of cancer treatment in people with solid tumors.
检索策略
We searched CENTRAL, MEDLINE, and Embase and ongoing trials registers, together with reference checking, in June 2025. There were no restrictions on language or publication status.
作者结论
There is moderate‐certainty evidence that primary prophylaxis G-CSF or GM-CSF likely reduces risk of infection versus control. In contrast, low- to moderate-certainty evidence suggests little to no improvement in overall survival and FFTF, and likely little to no difference between groups in all-cause mortality during chemotherapy. Regarding adverse events, moderate-certainty evidence shows a likely large increase in risk of bone pain.
Data on the effects of prophylaxis G-CSF or GM-CSF compared to control on duration of hospitalization were inadequate to draw any conclusions, and no studies evaluated quality of life. We identified no new ongoing studies, and the number of recent publications is limited. Further research in this field is warranted.
资助
This Cochrane review was funded by the "Innovation Star" project of outstanding graduate students in Gansu Province (2023CXZX-142), China.
注册
Protocol was available via 10.1002/14651858.CD015656.




